The stentless porcine aortic valve prostheses have the potential to provide superior hemodynamic function and durability. Our institution was a trial site for the investigational device exemption (IDE) for 2 of the 3 stentless valve bioprostheses and has clinical experience in all 3 valves that are soon to be available. From July 1996 to January 2001, we have implanted 213 porcine stentless valves: the Toronto SPV (159), the Freestyle (20), and the Prima Plus (34) (current IDE). Fifty-five percent of these patients had concomitant coronary artery bypass graft procedures, 44% had isolated aortic valve replacements, and 3 patients required aortic valve and mitral valve procedures. Fifty-nine percent of the patients were men, 9% of procedures were reoperations, and 22% of patients were in New York Heart Association classification III or IV preoperatively. Extubation occurred within 5 hours for 52% of patients, median cardiothoracic intensive care unit length of stay was 1 day, and postoperative length of stay was 6 days. Reoperations for bleeding occurred in 5.3% of patients (0 in the past 12 months), atrial fibrillation in 28.2%, and permanent neurologic deficit in 1.9%. No patients required valve-related reoperations or had either sepsis or sternal infections. Operative mortality was 1.4%. We have also analyzed a subset of patients who had minimally invasive aortic valve replacement versus the standard approach and found no important differences in mortality (none), postoperative complications, cardiopulmonary bypass, or cross-clamp times. There was a trend towards earlier ambulation, less atrial fibrillation (15.8% v 24.1%), and earlier hospital discharge (5.6 days v 7.2 days). We conclude that excellent results were obtained with all 3 stentless aortic valve bioprostheses. Hospital events should be predictably low in elderly patients and those requiring concomitant procedures. Stentless aortic valve bioprostheses can be incorporated into regular cardiac surgical practice with the techniques described.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/stcs.2001.27473 | DOI Listing |
Int J Cardiol Heart Vasc
February 2025
Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
Background: Epicardial fat tissue (EFT) is an active organ that can affect cardiac function and structure through endocrine, paracrine, and proinflammatory mechanisms. We hypothesized that greater thickness of EFT may harm the recovery of left ventricular (LV) systolic function in patients with severe aortic stenosis (AS) and reduced LV ejection fraction (EF ≤ 50 %) undergoing transcatheter aortic valve implantation (TAVI).
Methods: A sixty six patients with severe AS and 20 % ≥ LVEF ≤ 50 % who underwent TAVI were included.
JACC Adv
February 2025
Division of Cardiology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Gyeonggi-do, Republic of Korea.
Rev Cardiovasc Med
January 2025
Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital Ganzhou Hospital, Guangdong Academy of Medical Sciences, 341000 Ganzhou, Jiangxi, China.
Background: Prognosis assessments for transcatheter aortic valve implantation (TAVI) patients remain challenging, particularly as the indications for TAVI expand to lower-risk patients. This study assessed the prognostic value of the tricuspid regurgitation impact on outcomes (TRIO) score in patients after TAVI.
Methods: This single-center study included 530 consecutive patients who underwent TAVI.
Rev Cardiovasc Med
January 2025
Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
With the aging of the general population and the rise in surgical and transcatheter aortic valve replacement, there will be an increase in the prevalence of prosthetic aortic valves. Patients with prosthetic aortic valves can develop a wide range of unique pathologies compared to the general population. Accurate diagnosis is necessary in this population to generate a comprehensive treatment plan.
View Article and Find Full Text PDFCureus
December 2024
Cardiology, Pakistan Navy Station Shifa, Karachi, PAK.
Transcatheter aortic valve implantation (TAVI) involves complex decisions regarding perioperative anticoagulation, with continuation or interruption of oral anticoagulation presenting distinct risks and benefits. This systematic review and meta-analysis compared the clinical outcomes of these two strategies during TAVI. We conducted a comprehensive literature search across multiple electronic databases, including PubMed, Embase, Cochrane Library, and Web of Science, from inception to November 2024.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!